NCT06628726

Brief Summary

  1. 1.Identification and characterization of histopathological features of liver in cases of PNJ.
  2. 2.Assessment of key histological features in liver biopsy as diagnostic parameters in differentiating intra-hepatic and extra-hepatic causes of PNJ.
  3. 3.Evaluation of role of liver biopsy as a diagnostic tool in conjunction with clinical and laboratory findings.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Nov 2024

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 3, 2024

Completed
5 days until next milestone

First Posted

Study publicly available on registry

October 8, 2024

Completed
24 days until next milestone

Study Start

First participant enrolled

November 1, 2024

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2025

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2025

Completed
Last Updated

October 8, 2024

Status Verified

October 1, 2024

Enrollment Period

1 year

First QC Date

October 3, 2024

Last Update Submit

October 4, 2024

Conditions

Keywords

liver biopsy in neonatal jaundiceNeonatal Cholestasisliver biopsy

Outcome Measures

Primary Outcomes (1)

  • Identification of the key histopathological features in liver biopsy

    Identification of the key histopathological features in liver biopsy that aid in differentiation intra-hepatic and extra-hepatic causes of persistent neonatal jaundice (PNJ).

    baseline

Secondary Outcomes (1)

  • Evaluation of significance of liver biopsy as a diagnostic tool

    baseline

Study Arms (1)

Neonates

EXPERIMENTAL

Neonates with persistent neonatal jaundice underwent liver biopsy

Diagnostic Test: Liver biopsy

Interventions

Liver biopsyDIAGNOSTIC_TEST

surgical biopsy from liver

Also known as: Liver wedge biopsy, Liver core biopsy, Liver incisional biopsy
Neonates

Eligibility Criteria

Age1 Month - 1 Year
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • All cases presented with persistent neonatal jaundice in the first year of life in 5 years interval (2019-2023), received at Surgical Pathology Laboratory at Assiut University Hospitals, Egypt.

You may not qualify if:

  • Patients older than one year.
  • Patients who underwent liver biopsy in the same age group but were not diagnosed as Persistent Neonatal Jaundice.
  • Patients with deficient clinical data.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (3)

  • Mansour E, Eissa AN, Nofal LM, Kharboush I, Reda AA. Morbidity and mortality of low-birth-weight infants in Egypt. East Mediterr Health J. 2005 Jul;11(4):723-31.

    PMID: 16700389BACKGROUND
  • Fawaz R, Baumann U, Ekong U, Fischler B, Hadzic N, Mack CL, McLin VA, Molleston JP, Neimark E, Ng VL, Karpen SJ. Guideline for the Evaluation of Cholestatic Jaundice in Infants: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 2017 Jan;64(1):154-168. doi: 10.1097/MPG.0000000000001334.

    PMID: 27429428BACKGROUND
  • Ali KM, Zalata KR, Barakat T, Elzeiny SM. Pathologic approach to Neonatal cholestasis with a simple scoring system for biliary atresia. Virchows Arch. 2024 Jan;484(1):93-102. doi: 10.1007/s00428-023-03704-5. Epub 2023 Nov 27.

    PMID: 38008855BACKGROUND

MeSH Terms

Conditions

Jaundice, Neonatal

Condition Hierarchy (Ancestors)

Hyperbilirubinemia, NeonatalInfant, Newborn, DiseasesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesHyperbilirubinemiaPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Moemen M Hafez, M.D.

    Faculty of Medicine, Assiut University, Assiut, Egypt

    STUDY DIRECTOR
  • Abeer M Refaiy, M.D.

    Faculty of Medicine, Assiut University, Assiut, Egypt

    STUDY DIRECTOR

Central Study Contacts

Nourhan H Fouad, MBBCh

CONTACT

Abeer M Refaiy, M.D.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Doctor

Study Record Dates

First Submitted

October 3, 2024

First Posted

October 8, 2024

Study Start

November 1, 2024

Primary Completion

November 1, 2025

Study Completion

December 1, 2025

Last Updated

October 8, 2024

Record last verified: 2024-10